LONDON, Nov 12 (Reuters) - An experimental drug fromGlaxoSmithKline, designed to fight heart disease in anew way, failed to meet its main goal in the first of two biglate-stage clinical studies, the company said on Tuesday.
Darapladib did, however, produce greater reductions inserious coronary events in some of the pre-defined secondaryendpoints that GSK said required further analysis.
The once-daily pill, which is designed to prevent heartattacks and strokes by fighting clogged arteries in a completelydifferent way from cholesterol-lowering drugs, has been viewedby analysts as a high-risk project.
Glaxosmithkline (GSK)
